Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315023 | 0.90 | P2RX7 (0.52) | P2RX7MAPK1 | |
| SCHEMBL253558 | 0.78 | P2RX7 (0.46) | P2RX7MAPK1 | |
| SCHEMBL15465801 | 0.70 | P2RX7 (0.46) | P2RX7MAPK1 | |
| SCHEMBL9282053 | 0.69 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL13856950 | 0.69 | — | — | |
| SCHEMBL26341598 | 0.68 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL25217559 | 0.66 | P2RX7 (0.44) | P2RX7MAPK1 | |
| SCHEMBL23532485 | 0.62 | P2RX7 (0.35) | P2RX7 | |
| SCHEMBL422542 | 0.62 | P2RX7 (0.89) | P2RX7MAPK1 | |
| SCHEMBL19383987 | 0.61 | P2RX7 (0.85) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268992-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | P2RX7 1501/4885MAPK1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.